Publications by authors named "Clive Buckle"

Claim this Profile
A
ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
Darren L Lath, Clive H Buckle, Holly R Evans, Matthew Fisher, Jenny M Down

PLoS One· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells.
Huda F AlShaibi, Farid Ahmed, Clive Buckle, Ann C M Fowles, Jalaluddin Awlia

Biotechnol Appl Biochem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma.
Polly J Talley, Andrew D Chantry, Clive H Buckle

Br Med Bull· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloma bone disease: pathogenesis, current treatments and future targets.
Rebecca E Walker, Michelle A Lawson, Clive H Buckle, John A Snowden, Andrew D Chantry

Br Med Bull· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
Clive Henry Buckle, Evy De Leenheer, Michelle Anne Lawson, Kwee Yong, Neil Rabin

PLoS One· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Deborah J Heath, Andrew D Chantry, Clive H Buckle, Les Coulton, John D Shaughnessy

J Bone Miner Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis